Quick Answer
OCULAR THERAPEUTIX, INC reported Research And Development Expense of $197.10 million for the year ending 2025.
- OCULAR THERAPEUTIX, INC showed an increase of +54.4% in Research And Development Expense from 2024 to 2025.
- This data is from OCULAR THERAPEUTIX, INC's annual report (Form 10-K), filed with the SEC on February 5, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), OCULAR THERAPEUTIX, INC's Research And Development Expense has grown by 1,607.9%.
- Historical annual values: Fiscal year 2025: $197.10 million | Fiscal year 2024: $127.64 million | Fiscal year 2023: $61.06 million | Fiscal year 2022: $53.46 million | Fiscal year 2021: $50.08 million | Fiscal year 2020: $28.69 million | Fiscal year 2019: $41.09 million | Fiscal year 2018: $36.92 million | Fiscal year 2017: $30.88 million | Fiscal year 2016: $27.07 million | Fiscal year 2015: $26.61 million | Fiscal year 2014: $18.88 million | Fiscal year 2013: $10.52 million | Fiscal year 2012: $11.54 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: